Slideshow

Potential New Biomarker for the Diagnosis of ALS

Author(s):

Veronica Hackethal, MD

A new study has found that an RNA-binding protein called TDP-43 could be a promising new biomarker for diagnosing amyotropic lateral sclerosis.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!
Related Videos
Related Content
Enrollment Complete for Phase 2b/3 COMBAT-ALS Study of PDE4 Inhibitor Ibudilast
August 28th 2025

Enrollment Complete for Phase 2b/3 COMBAT-ALS Study of PDE4 Inhibitor Ibudilast

Marco Meglio
Episode 146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care
August 28th 2025

Episode 146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care

Marco Meglio John Sims, MD
NPTX2 Identified as Synaptic Biomarker Implicated in ALS Survival, Disease Progression
August 28th 2025

NPTX2 Identified as Synaptic Biomarker Implicated in ALS Survival, Disease Progression

Marco Meglio
Episode 140: Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress
August 28th 2025

Episode 140: Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress

Marco Meglio Elizabeth Head, PhD
COYA 302 Heads to Phase 2 Trial of ALS Following IND Acceptance
August 28th 2025

COYA 302 Heads to Phase 2 Trial of ALS Following IND Acceptance

Marco Meglio
Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data
August 28th 2025

Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data

Marco Meglio
© 2025 MJH Life Sciences

All rights reserved.